High on Treatment Platelet Reactivity

Heart Lung and Circulation

Volumn 21, Issue 1, 2012, Pages 12-21

  Ait Mokhtar, Omar ^a   Bonello, Laurent ^a   Benamara, Saida ^b   Paganelli, Franck ^a  

^a HÔPITAL NORD   (France)

^b Centre Hospitalier et Universitaire de Beni Messous Algiers   (Algeria)

Author keywords

Platelet function; Platelet reactivity; Platelet testing

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; OMEPRAZOLE; PLACEBO; PRASUGREL; PROTON PUMP INHIBITOR; PURINERGIC P2Y12 RECEPTOR; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE;

ACUTE CORONARY SYNDROME; BLEEDING; BODY MASS; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; GASTROINTESTINAL HEMORRHAGE; HUMAN; LOADING DRUG DOSE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; REVIEW; STENT THROMBOSIS; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ANGIOPLASTY, BALLOON, CORONARY; ASPIRIN; COMBINED MODALITY THERAPY; CYCLOOXYGENASE INHIBITORS; DRUG INTERACTIONS; DRUG RESISTANCE; HUMANS; MYOCARDIAL ISCHEMIA; PLATELET ACTIVATION; PLATELET FUNCTION TESTS; PURINERGIC P2Y RECEPTOR ANTAGONISTS; STENTS; THROMBOSIS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84855830425     PISSN: 14439506     EISSN: 14442892     Source Type: Journal    
DOI: 10.1016/j.hlc.2011.08.069     Document Type: Review

References (91)

1. Serruys P.W., Strauss B.H., Beatt K.J., Bertrand M.E., Puel J., Rickards A.F., et al. Angiographic follow-up after placement of a self-expanding coronary-artery stent. N Engl J Med 1991, 324:13-17.
2. Haude M., Erbel R., Issa H., Straub U., Rupprecht H.J., Treese N., et al. Subacute thrombotic complications after intracoronary implantation of Palmaz-Schatz stents. Am Heart J 1993, 126:15-22.
3. Gurbel P.A., Becker R.C., Mann K.G., Steinhubl S.R., Michelson A.D. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol 2007, 50:1822-1834.
4. Savi P., Herbert J.M. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005, 31:174-183.
5. Michelson A.D., Frelinger A.L., Furman M.I. Current options in platelet function testing. Am J Cardiol 2006, 98(10A):4N-10N.
6. Michelson A.D. Methods for the measurement of platelet function. Am J Cardiol 2009, 103(3 Suppl.):20A-26A.
7. Serebruany V.L., Steinhubl S.R., Berger P.B., Malinin A.I., Bhatt D.L., Topol E.J. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005, 45:246-251.
8. Price M.J. Bedside evaluation of thienopyridine antiplatelet therapy. Circulation 2009, 119:2625-2632.
9. Blindt R., Stellbrink K., de Taeye A., Muller A., Kieffer P., Yagmur E., et al. The signification of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost 2007, 98:1329-1334.
10. Geisler T., Grass D., Bigalke B., Stellos K., Drosch T., Dietz K., et al. The residual platelet aggregation after deployment of intracoronary stent (PREDICT) score. J Thromb Haemost 2008, 6:54-61.
11. Price M.J., Endemann S., Gollapudi R.R., Valencia R., Stinis C.T., Levisay J.P., et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur Heart J 2008, 29:992-1000.
12. Bonello L., Camoin-Jau L., Arques S., Boyer C., Panagides D., Wittenberg O., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 2008, 51:1404-1411.
13. Sibbing D., Braun S., Morath T., Mehilli J., Vogt W., Schömig A., et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol 2009, 53:849-856.
14. Cuisset T., Frere C., Quilici J., Gaborit B., Castelli C., Poyet R., et al. Predictive values of post-treatment adenosinediphosphate induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. Am J Cardiol 2009, 104:1078-1082.
15. Bonello L., Paganelli F., Arpin-Bornet M., Auquier P., Sampol J., Dignat-George F., et al. Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost 2007, 5:1630-1636.
16. Patti G., Nusca A., Mangiacapra F., Gatto L., D'Ambrosio A., Di Sciascio G. Point-of care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the ARMYDA-PRO (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 2008, 52:1128-1133.
17. Angiolillo D.J., Shoemaker S.B., Desai B., Yuan H., Charlton R.K., Bernardo E., et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007, 115:708-716. 727.
18. Michelson A.D., Frelinger A.L., Braunwald E., Downey W.E., Angiolillo D.J., Xenopoulos N.P., et al. TRITON-TIMI 38 Investigators. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009, 30(July (14)):1753-1763. [Epub 2009 May 12].
19. Wang T.H., Bhatt D.L., Topol E.J. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006, 27:647-654.
20. Gawaz M., Neumann F.J., Ott I., Schiessler A., Schomig A. Platelet function in acute myocardial infarction treated with direct angioplasty. Circulation 1996, 93:229-237.
21. Serebruany V.L., Malinin A.I., Jerome S.D., Lowry D.R., Morgan A.W., Sane D.C., et al. Effect of clopidogrel and aspirin combination versus aspirin alone on platelet aggregation and major receptor expression in patients with heart failure: the Plavix Use for Treatment Of Congestive Heart Failure (PLUTO-CHF) trial. Am Heart J 2003, 146:713-720.
22. Soffer D., Moussa I., Harjai K.J., Boura J.A., Dixon S.R., Grines C.L., et al. Impact of angina class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: do we need more aggressive dosing regimens in unstable angina?. Cathet Cardiovasc Intervent 2003, 59:21-25.
23. Poulsen T.S., Vinholt P., Mickley H., Korsholm L., Kristensen S.R., Damkier P. Existence of a clinically relevant interaction between clopidogrel and HMG-CoA reductase inhibitors? Reevaluating the evidence. Basic Clin Pharmacol Toxicol 2005, 96:103-110.
24. Gurbel P.A., Bliden K.P., O'Connor C.M. Clopidogrel for coronary stenting. Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003, 107:2908-2913.
25. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Barrera Ramirez C., Sabate M., Fernandez C., et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loadingdose be weight adjusted?. J Invasive Cardiol 2004, 16:169-174.
26. Cuisset T., Frere C., Quilici J., Morange P.E., Camoin L., Bali L., et al. Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Thromb Res 2009, 123:597-603.
27. Sibbing D., von Beckerath O., Schömig A., Kastrati A., von Beckerath N. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600mg of Clopidogrel before percutaneous coronary intervention. Am J Cardiol 2007, 100(2):203-205.
28. Bonello-Palot N., Armero S., Paganelli F., Mancini J., De Labriolle A., Bonello C., et al. Relation of body mass index to high on-treatment platelet reactivity and of failed Clopidogrel dose adjustment according to platelet reactivity monitoring in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009, 104(11):1511-1515.
29. Scherrer U., Nussberger J., Torriani S., Waeber B., Darioli R., Hofstetter J.R., et al. Effect of weight reduction in moderately overweight patients on recorded ambulatory blood pressure and free cytosolic platelet calcium. Circulation 1991, 83:552-558.
30. Kotlyar M., Carson S.W. Effects of obesity on the cytochromes P450 enzyme system. Int J Pharmacol Ther 1999, 37:8-19.
31. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramírez C., Sabaté M., Jimenez-Quevedo P., et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005, 54:2430-2435.
32. Angiolillo D.J., Bernardo E., Ramírez C., Costa M.A., Sabaté M., Jimenez-Quevedo P., et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006, 48:298-304.
33. Geisler T., Anders N., Paterok M., Langer H., Stellos K., Lindemann S., et al. Platelet response to clopidogrel is attenuated in diabetic patients undergoing coronary stent implantation. Diabetes Care 2007, 30:372-374.
34. Serebruany V., Pokov I., Kuliczkowski W., Chesebro J., Badimon J. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost 2008, 100:76-82.
35. Ferroni P., Basili S., Falco A., Davì G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004, 2(August (8)):1282-1291. [Review].
36. Ferreira I.A., Eibrecht K.L., Mocking A.I., Kroner C., Akkerman J.W. IRS-1 mediates inhibition of Ca+2 metabolization of insulin via the inhibitory G protein Gi. J Biol Chem 2004, 279:3254-3264.
37. Ferreira I.A., Mocking A.I., Feijge M.A., Gorter G., van Haeften T.W., Heemskerk J.W., et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006, 26:417-422.
38. Ishizaki T., Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole. Aliment Pharmacol Ther 1999, 13(3):27-36.
39. Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitors-focus on rabeprazole. Aliment Pharmacol Ther 2004, 20(Suppl. 6):11-19.
40. Gilard M., Arnaud B., Cornily J.C., Le Gal G., Lacut K., Le Calvez G., et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008, 51(3):256-260.
41. Gilard M., Arnaud B., Le Gal G., Abgrall J.F., Boschat J. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost 2006, 4(11):2508-2509.
42. Simon T., Verstuyft C., Mary-Krause M., Quteineh L., Drouet E., Méneveau N., et al. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009, 360(4):363-375.
43. Collet J.P., Hulot J.S., Pena A., Villard E., Esteve J.B., Silvain J., et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: A cohort study. Lancet 2009, 373(9660):309-317.
44. Siller-Matula J.M., Spiel A.O., Lang I.M., Kreiner G., Christ G., Jilma B. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009, 157(1):148. e1-5.
45. Kwok C.S., Loke Y.K. Meta-analysis: the effects of proton pump inhibitors on cardiovascular events and mortality in patients receiving Clopidogrel. Aliment Pharmacol Ther 2010, 31(8):810-823.
46. Bhatt D.L., Cryer B.L., Contant C.F. Clopidogrel with or without omeprazole in coronary artery disease, COGENT Investigators. N Engl J Med 2010, 363(November (20)):1909-1917. [Epub 2010 October 6].
47. Siller-Matula J.M., Lang I., Christ G., Jilma B. Calcium-channel blockers reduce the antiplatelet effect of clopidogrel. J Am Coll Cardiol 2008, 52(19):1557-1563.
48. Olesen J.B., Gislason G.H., Charlot M.G. Calcium-channel blockers do not alter the clinical efficacy of Clopidogrel after myocardial infarction: a Nationwide Cohort Study. J Am Coll Cardiol 2011, 57(January):409-417.
49. French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009, 360:363-375.
50. Hochholzer W., Trenk D., Frundi D., Blanke P., Fischer B., Andris K., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 2005, 111:2560-2564.
51. Collet J.P., Silvain J., Landivier A., Tanguy M.L., Cayla G., Bellemain A., et al. Dose effect of clopidogrel reloading in patients already on 75-mg maintenance dose: the reload with Clopidogrel before coronary angioplasty in subjects treated long term with dual antiplatelet therapy (RELOAD) study. Circulation 2008, 118:1225-1233.
52. Angiolillo D.J., Fernández-Ortiz A., Bernardo E., Ramírez C., Sabaté M., Bañuelos C., et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J 2004, 25:1903-1910.
53. Gurbel P.A., Tantry U.S. Drug insight: Clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med 2006, 3:387-395.
54. Nebert D.W., Russell D.W. Clinical importance of the cytochromes P450. Lancet 2002, 360(9340):1155-1162.
55. Nguyen T.A., Diodati J.G., Pharand C. Resistance to clopidogrel: a review of the evidence. J Am Coll Cardiol 2005, 45(8):1157-1164.
56. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., Ramírez C., Cavallari U., Trabetti E., et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Haemost 2005, 116(60):491-497.
57. Von Beckerath N., Taubert D., Pogatsa-Murray G., Schömig E., Kastrati A., Schömig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) trial. Circulation 2005, 112(19):2946-2950.
58. Bonello L., Bonello-Palot N., Armero S., Bonello C., Ait Mokhtar O., Arques S., et al. Impact of P2Y12-ADP receptor polymorphism on the efficacy of clopidogrel doseadjustment according to platelet reactivity monitoring in coronary artery disease patients. Thromb Res 2010, 125(4):e167-e170.
59. Von Beckerath N., Von Beckerath O., Koch W., Eichinger M., Schömig A., Kastrati A. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphateinduced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 2005, 16(3):199-204.
60. Hulot J.S., Bura A., Villard E., Azizi M., Remones V., Goyenvalle C., et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006, 108(7):2244-2247.
61. Brandt J.T., Close S.L., Iturria S.J., Payne C.D., Farid N.A., Ernest C.S., et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J Thromb Haemost 2007, 5(12):2429-2436.
62. Umemura K., Furuta T., Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics to an active metabolite of clopidogrel in healthy subjects. J Thromb Haemost 2008, 6(8):1439-1441.
63. Giusti B., Gori A.M., Marcucci R., Saracini C., Sestini I., Paniccia R., et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 +12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet Genomics 2007, 17(12):1057-1064.
64. Frere C., Cuisset T., Morange P.E., Quilici J., Camoin-Jau L., Saut N., et al. Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome. Am J Cardiol 2008, 101(8):1088-1093.
65. Trenk D., Hochholzer W., Fromm M.F., Chialda L.E., Pahl A., Valina C.M., et al. Cytochrome P450 2C19 681GNA polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents. J Am Coll Cardiol 2008, 51(20):1925-1934.
66. Trenk D., Hochholzer W., Frundi D., Stratz C., Valina C.M., Bestehorn H.P., et al. Impact of cytochrome P450 3A4-metabolized statins on the antiplatelet effect of a 600-mg loading dose clopidogrel and on clinical outcome in patients undergoing elective coronary stent placement. Thromb Haemost 2008, 99(1):174-181.
67. Mega J.L., Close S.L., Wiviott S.D., Shen L., Walker J.R., Simon T., et al. Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet 2010, 10.1016/S0140-6736(10)61273-1.
68. Wallentin L., James S., Storey R.F., Armstrong M., Barratt B.J., Horrow J., et al. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet 2010, 376(9749):1320-1328.
69. Barragan P., Bouvier J.L., Roquebert P.O., Macaluso G., Commeau P., Comet B., et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003, 59(3):295-302.
70. Matetzky S., Shenkman B., Ghetta V., Shechter M., Bienart R., Goldenberg I., et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004, 109:3171-3175.
71. Bliden K.P., DiChiara J., Tantry U.S., Bassi A.K., Chaganti S.K., Gurbel P.A. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?. J Am Coll Cardiol 2007, 49:657-666.
72. Hochholzer W., Trenk D., Bestehorn H.P., Fischer B., Valina C.M., Ferenc M., et al. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 2006, 48:1742-1750.
73. Buonamici P., Marcucci R., Migliorini A., Gensini G.F., Santini A., Paniccia R., et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J Am Coll Cardiol 2007, 49:2312-2317.
74. Lev E.I., Alviar C.L., Arikan M.E., Dave B.P., Granada J.F., DeLao T., et al. Platelet reactivity in patients with subacute stent thrombosis compared with nonstent-related acute myocardial infarction. Am Heart J 2007, 153:e1-e6.
75. Geisler T., Langer H., Wydymus M., Göhring K., Zürn C., Bigalke B., et al. Low response to clopidogrel is associated with cardiovascular outcome after coronary stent implantation. Eur Heart J 2006, 27:2420-2425.
76. Collet J.P., Cayla G., Cuisset T., Elhadad S., Rangé G., Vicaut E., et al. Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study. Am Heart J 2011, 161(January (1)):5-12. e5.
77. Cuisset T., Frere C., Quilici J., Morange P.E., Nait-Saidi L., Carvajal J., et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-ST-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 2006, 48:1339-1345.
78. von Beckerath N., Kastrati A., Wieczorek A., Pogatsa-Murray G., Sibbing D., Graf I., et al. A double-blind, randomized study on platelet aggregation in patients treated with a daily dose of 150 or 75mg of clopidogrel for 30 days. Eur Heart J 2007, 28:1814-1819.
79. Patti G., Colonna G., Pasceri V., Pepe L.L., Montinaro A., Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty) study. Circulation 2005, 111:2099-2106.
80. Angiolillo D.J., Shoemaker S.B., Desai B., Yuan H., Charlton R.K., Bernardo E., et al. Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study. Circulation 2007, 115:708-716.
81. Lemesle G., Delhaye C., Sudre A., Broucqsault D., Rosey G., Bauters C., et al. Impact of high loading and maintenance dose of clopidogrel within the first 15 days after percutaneous coronary intervention on patient outcome. Am Heart J 2009, (February (2)):375-382.
82. Bonello L., Palot-Bonello N., Armero S., Camoin-Jau L., Paganelli F. Impact of loading dose adjustment on platelet reactivity in homozygotes of the 2C19 2 loss of function polymorphism. Int J Cardiol 2010, 145(1):165-166.
83. Price M.J., Berger P.B., Teirstein P.S., Tanguay J.F., Angiolillo D.J., Spriggs D., et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.; GRAVITAS Investigators. JAMA 2011, 305(March (11)):1097-1105.
84. Tanaka T., Ishikawa T., Hagiwara M., Onoda K., Itoh H., Hidaka H. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle. Pharmacology 1988, 36:313-320.
85. Park S.W., Lee C.W., Kim H.S., Lee H.J., Park H.K., Hong M.K., et al. Comparison of cilostazol versus ticlopidine therapy after stent implantation. Am J Cardiol 1999, 84:511-514.
86. Lee S.W., Park S.W., Hong M.K., Lee C.W., Kim Y.H., Park J.H., et al. Comparison of cilostazol and clopidogrel after successful coronary stenting. Am J Cardiol 2005, 95:859-862.
87. Lee S.W., Park S.W., Hong M.K., Kim Y.H., Lee B.K., Song J.M., et al. Triple versus dual antiplatelet therapy after coronary stenting: impact on stent thrombosis. J Am Coll Cardiol 2005, 46:1833-1837.
88. Cuisset T., Frere C., Quilici J., Morange P.E., Mouret J.P., Bali L., et al. Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders: a prospective, randomized study. JACC Cardiovasc Interv 2008, 1:649-653.
89. TRITON-TIMI 38 Investigators Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J 2009, 30:1753-1763.
90. Wiviott S.D., Braunwald E., McCabe C.H., Montalescot G., Ruzyllo W., Gottlieb S., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015.
91. Wallentin L., Becker R.C., Budaj A., Cannon C.P., Emanuelsson H., Held C., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2000, 361:1045-1057.